Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ.
Douglas RS, et al.
Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21.
Ophthalmology. 2022.
PMID: 34688699
Free article.
Clinical Trial.